Which has stronger earnings & valuation, RGEN or ZBIO?

Repligen has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Repligen $785.10M 10.77 $48.89M $0.73 205.18 Zenas BioPharma $10M 198.35 -$377.74M -$8.47 N/A

Does the media prefer RGEN or ZBIO?

In the previous week, Repligen had 20 more articles in the media than Zenas BioPharma. MarketBeat recorded 24 mentions for Repligen and 4 mentions for Zenas BioPharma. Repligen's average media sentiment score of 1.03 beat Zenas BioPharma's score of 0.64 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 12 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LGND or ZBIO?

In the previous week, Ligand Pharmaceuticals had 6 more articles in the media than Zenas BioPharma. MarketBeat recorded 10 mentions for Ligand Pharmaceuticals and 4 mentions for Zenas BioPharma. Ligand Pharmaceuticals' average media sentiment score of 1.21 beat Zenas BioPharma's score of 0.64 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ZBIO or CLDX more profitable?

Celldex Therapeutics' return on equity of -50.72% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Zenas BioPharma N/A -99.99% -58.06% Celldex Therapeutics N/A -50.72% -46.59%

Does the media favor ZBIO or CLDX?

In the previous week, Celldex Therapeutics had 5 more articles in the media than Zenas BioPharma. MarketBeat recorded 9 mentions for Celldex Therapeutics and 4 mentions for Zenas BioPharma. Celldex Therapeutics' average media sentiment score of 1.15 beat Zenas BioPharma's score of 0.64 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZBIO or BCRX?

In the previous week, BioCryst Pharmaceuticals had 4 more articles in the media than Zenas BioPharma. MarketBeat recorded 8 mentions for BioCryst Pharmaceuticals and 4 mentions for Zenas BioPharma. BioCryst Pharmaceuticals' average media sentiment score of 1.33 beat Zenas BioPharma's score of 0.64 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, INVA or ZBIO?

Innoviva has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 3.74 $271.17M $6.01 3.47 Zenas BioPharma $10M 198.35 -$377.74M -$8.47 N/A

Does the media refer more to INVA or ZBIO?

In the previous week, Innoviva had 5 more articles in the media than Zenas BioPharma. MarketBeat recorded 9 mentions for Innoviva and 4 mentions for Zenas BioPharma. Innoviva's average media sentiment score of 0.96 beat Zenas BioPharma's score of 0.64 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zenas BioPharma (ZBIO) Competitors

$31.42 +0.29 (+0.93%)

Closing price 04:00 PM Eastern

Extended Trading

$30.54 -0.89 (-2.82%)

As of 04:10 PM Eastern

Compare

ZBIO vs. RGEN, LGND, CLDX, BCRX, and INVA

Should you buy Zenas BioPharma stock or one of its competitors? MarketBeat compares Zenas BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zenas BioPharma include Repligen (RGEN), Ligand Pharmaceuticals (LGND), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), and Innoviva (INVA). These companies are all part of the "biotechnology" industry.

How does Zenas BioPharma compare to Repligen?

Repligen (NASDAQ:RGEN) and Zenas BioPharma (NASDAQ:ZBIO) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Repligen has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -1.03, suggesting that its stock price is 203% less volatile than the broader market.

Repligen has a net margin of 5.29% compared to Zenas BioPharma's net margin of 0.00%. Repligen's return on equity of 5.30% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	5.29%	5.30%	3.79%
Zenas BioPharma	N/A	-99.99%	-58.06%

Repligen has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$785.10M	10.77	$48.89M	$0.73	205.18
Zenas BioPharma	$10M	198.35	-$377.74M	-$8.47	N/A

In the previous week, Repligen had 20 more articles in the media than Zenas BioPharma. MarketBeat recorded 24 mentions for Repligen and 4 mentions for Zenas BioPharma. Repligen's average media sentiment score of 1.03 beat Zenas BioPharma's score of 0.64 indicating that Repligen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	12 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.6% of Repligen shares are owned by institutional investors. 0.6% of Repligen shares are owned by insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Repligen currently has a consensus price target of $166.43, suggesting a potential upside of 11.12%. Zenas BioPharma has a consensus price target of $44.29, suggesting a potential upside of 40.95%. Given Zenas BioPharma's higher probable upside, analysts plainly believe Zenas BioPharma is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.94
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

Repligen beats Zenas BioPharma on 14 of the 17 factors compared between the two stocks.

How does Zenas BioPharma compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Zenas BioPharma (NASDAQ:ZBIO) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Ligand Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$274.48M	21.96	$124.45M	$7.37	40.81
Zenas BioPharma	$10M	198.35	-$377.74M	-$8.47	N/A

Ligand Pharmaceuticals has a net margin of 55.95% compared to Zenas BioPharma's net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 16.19% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	55.95%	16.19%	11.13%
Zenas BioPharma	N/A	-99.99%	-58.06%

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Ligand Pharmaceuticals had 6 more articles in the media than Zenas BioPharma. MarketBeat recorded 10 mentions for Ligand Pharmaceuticals and 4 mentions for Zenas BioPharma. Ligand Pharmaceuticals' average media sentiment score of 1.21 beat Zenas BioPharma's score of 0.64 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -1.03, meaning that its stock price is 203% less volatile than the broader market.

Ligand Pharmaceuticals currently has a consensus price target of $326.00, suggesting a potential upside of 8.38%. Zenas BioPharma has a consensus price target of $44.29, suggesting a potential upside of 40.95%. Given Zenas BioPharma's higher probable upside, analysts clearly believe Zenas BioPharma is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

Ligand Pharmaceuticals beats Zenas BioPharma on 13 of the 16 factors compared between the two stocks.

How does Zenas BioPharma compare to Celldex Therapeutics?

Zenas BioPharma (NASDAQ:ZBIO) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Celldex Therapeutics' return on equity of -50.72% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Celldex Therapeutics	N/A	-50.72%	-46.59%

Zenas BioPharma has a beta of -1.03, suggesting that its stock price is 203% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

Zenas BioPharma presently has a consensus price target of $44.29, suggesting a potential upside of 40.95%. Celldex Therapeutics has a consensus price target of $54.62, suggesting a potential upside of 39.82%. Given Zenas BioPharma's higher probable upside, research analysts clearly believe Zenas BioPharma is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Celldex Therapeutics had 5 more articles in the media than Zenas BioPharma. MarketBeat recorded 9 mentions for Celldex Therapeutics and 4 mentions for Zenas BioPharma. Celldex Therapeutics' average media sentiment score of 1.15 beat Zenas BioPharma's score of 0.64 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celldex Therapeutics has lower revenue, but higher earnings than Zenas BioPharma. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	198.35	-$377.74M	-$8.47	N/A
Celldex Therapeutics	$1.54M	1,990.79	-$258.76M	-$4.26	N/A

Summary

Celldex Therapeutics beats Zenas BioPharma on 11 of the 14 factors compared between the two stocks.

How does Zenas BioPharma compare to BioCryst Pharmaceuticals?

Zenas BioPharma (NASDAQ:ZBIO) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Zenas BioPharma currently has a consensus target price of $44.29, suggesting a potential upside of 40.95%. BioCryst Pharmaceuticals has a consensus target price of $20.80, suggesting a potential upside of 130.60%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

Zenas BioPharma has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -51.71%. BioCryst Pharmaceuticals' return on equity of -76.36% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

Zenas BioPharma has a beta of -1.03, meaning that its stock price is 203% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

In the previous week, BioCryst Pharmaceuticals had 4 more articles in the media than Zenas BioPharma. MarketBeat recorded 8 mentions for BioCryst Pharmaceuticals and 4 mentions for Zenas BioPharma. BioCryst Pharmaceuticals' average media sentiment score of 1.33 beat Zenas BioPharma's score of 0.64 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	198.35	-$377.74M	-$8.47	N/A
BioCryst Pharmaceuticals	$874.84M	2.62	$263.86M	-$1.78	N/A

Summary

BioCryst Pharmaceuticals beats Zenas BioPharma on 12 of the 16 factors compared between the two stocks.

How does Zenas BioPharma compare to Innoviva?

Innoviva (NASDAQ:INVA) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

In the previous week, Innoviva had 5 more articles in the media than Zenas BioPharma. MarketBeat recorded 9 mentions for Innoviva and 4 mentions for Zenas BioPharma. Innoviva's average media sentiment score of 0.96 beat Zenas BioPharma's score of 0.64 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.74	$271.17M	$6.01	3.47
Zenas BioPharma	$10M	198.35	-$377.74M	-$8.47	N/A

Innoviva currently has a consensus price target of $36.20, suggesting a potential upside of 73.54%. Zenas BioPharma has a consensus price target of $44.29, suggesting a potential upside of 40.95%. Given Innoviva's higher probable upside, analysts plainly believe Innoviva is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Innoviva has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -1.03, suggesting that its stock price is 203% less volatile than the broader market.

99.1% of Innoviva shares are held by institutional investors. 2.0% of Innoviva shares are held by insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Innoviva has a net margin of 119.89% compared to Zenas BioPharma's net margin of 0.00%. Innoviva's return on equity of 33.33% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Zenas BioPharma	N/A	-99.99%	-58.06%

Summary

Innoviva beats Zenas BioPharma on 12 of the 16 factors compared between the two stocks.

Get Zenas BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZBIO vs. The Competition

Export

Metric	Zenas BioPharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.98B	$3.56B	$6.80B	$13.02B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-3.71	7.36	279.72	25.54
Price / Sales	198.35	1,274.64	648.71	115.96
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	6.97	17.08	11.12	6.36
Net Income	-$377.74M	-$12.52M	$3.48B	$347.58M
7 Day Performance	-2.69%	2.52%	2.59%	3.17%
1 Month Performance	15.39%	-5.36%	-2.79%	-2.06%
1 Year Performance	86.91%	51.37%	64.29%	21.19%

Zenas BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZBIO Zenas BioPharma	3.4804 of 5 stars	$31.42 +0.9%	$44.29 +40.9%	+102.0%	$1.98B	$10M	N/A	N/A	News Coverage Upcoming Earnings
RGEN Repligen	3.8784 of 5 stars	$145.34 +10.9%	$165.36 +13.8%	+23.7%	$7.39B	$763.34M	161.49	2,000	Positive News Earnings Report High Trading Volume
LGND Ligand Pharmaceuticals	4.1473 of 5 stars	$296.28 -0.4%	$319.00 +7.7%	+120.0%	$5.96B	$274.48M	40.20	80	Positive News Upcoming Earnings Analyst Forecast Gap Up
CLDX Celldex Therapeutics	2.9965 of 5 stars	$35.58 -0.2%	$52.77 +48.3%	+69.9%	$2.80B	$1.54M	N/A	150	Upcoming Earnings
BCRX BioCryst Pharmaceuticals	3.8193 of 5 stars	$9.74 +1.7%	$20.80 +113.6%	+10.8%	$2.43B	$874.84M	N/A	530	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZBIO) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zenas BioPharma (ZBIO) Competitors

ZBIO vs. RGEN, LGND, CLDX, BCRX, and INVA

How does Zenas BioPharma compare to Repligen?

Summary

How does Zenas BioPharma compare to Ligand Pharmaceuticals?

Summary

How does Zenas BioPharma compare to Celldex Therapeutics?

Summary

How does Zenas BioPharma compare to BioCryst Pharmaceuticals?

Summary

How does Zenas BioPharma compare to Innoviva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBIO vs. The Competition

Zenas BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zenas BioPharma (ZBIO) Competitors

ZBIO vs. RGEN, LGND, CLDX, BCRX, and INVA

How does Zenas BioPharma compare to Repligen?

Which has more volatility and risk, RGEN or ZBIO?

Is RGEN or ZBIO more profitable?

Which has stronger earnings & valuation, RGEN or ZBIO?

Does the media prefer RGEN or ZBIO?

Do institutionals & insiders have more ownership in RGEN or ZBIO?

Do analysts recommend RGEN or ZBIO?

Summary

How does Zenas BioPharma compare to Ligand Pharmaceuticals?

Which has stronger valuation & earnings, LGND or ZBIO?

Is LGND or ZBIO more profitable?

Do institutionals and insiders hold more shares of LGND or ZBIO?

Does the media prefer LGND or ZBIO?

Which has more volatility and risk, LGND or ZBIO?

Do analysts rate LGND or ZBIO?

Summary

How does Zenas BioPharma compare to Celldex Therapeutics?

Is ZBIO or CLDX more profitable?

Which has more volatility & risk, ZBIO or CLDX?

Do analysts rate ZBIO or CLDX?

Does the media favor ZBIO or CLDX?

Which has stronger earnings and valuation, ZBIO or CLDX?

Summary

How does Zenas BioPharma compare to BioCryst Pharmaceuticals?

Do institutionals and insiders have more ownership in ZBIO or BCRX?

Do analysts prefer ZBIO or BCRX?

Is ZBIO or BCRX more profitable?

Which has more volatility & risk, ZBIO or BCRX?

Does the media favor ZBIO or BCRX?

Which has stronger earnings & valuation, ZBIO or BCRX?

Summary

How does Zenas BioPharma compare to Innoviva?

Does the media refer more to INVA or ZBIO?

Which has higher earnings & valuation, INVA or ZBIO?

Do analysts rate INVA or ZBIO?

Which has more risk & volatility, INVA or ZBIO?

Do insiders and institutionals have more ownership in INVA or ZBIO?

Is INVA or ZBIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBIO vs. The Competition

Zenas BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools